Cephalon reaches $1 billion milestone in annual revenue

02/17/2005 | Philadelphia Inquirer, The

Cephalon's announcement puts it in a league with only eight other U.S. biotechnology companies, and the firm's CEO said he expects revenues to double to $2 billion by the end of 2008. In the coming two years, Cephalon faces a loss of patent for two of its biggest products, Provigil and Actiq, and one analyst said the company would need to "ramp up sales in the attention-deficit market" and get approval of another drug now in Phase III clinical trials to offset the expected generic competition for Provigil and Actiq.

View Full Article in:

Philadelphia Inquirer, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
Catheter Engineer
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
MANAGER MEDICAL GAS COMPLIANCE AND SAFETY
Matheson Tri-Gas, Inc.
Houston, TX
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations